These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
516 related articles for article (PubMed ID: 20687620)
21. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546 [TBL] [Abstract][Full Text] [Related]
22. Natalizumab for relapsing remitting multiple sclerosis. Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773 [TBL] [Abstract][Full Text] [Related]
23. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F; JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034 [TBL] [Abstract][Full Text] [Related]
24. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Khoury SJ; Healy BC; Kivisäkk P; Viglietta V; Egorova S; Guttmann CR; Wedgwood JF; Hafler DA; Weiner HL; Buckle G; Cook S; Reddy S Arch Neurol; 2010 Sep; 67(9):1055-61. PubMed ID: 20837847 [TBL] [Abstract][Full Text] [Related]
25. [Long-term effects of glatiramer acetate in multiple sclerosis]. Brochet B Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510 [TBL] [Abstract][Full Text] [Related]
26. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Metz LM; Li D; Traboulsee A; Myles ML; Duquette P; Godin J; Constantin M; Yong VW; Mult Scler; 2009 Oct; 15(10):1183-94. PubMed ID: 19776092 [TBL] [Abstract][Full Text] [Related]
28. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Comi G; Filippi M; Wolinsky JS Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502 [TBL] [Abstract][Full Text] [Related]
29. History of modern multiple sclerosis therapy. Lublin F J Neurol; 2005 Sep; 252 Suppl 3():iii3-iii9. PubMed ID: 16170498 [TBL] [Abstract][Full Text] [Related]
30. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Clerico M; Faggiano F; Palace J; Rice G; Tintorè M; Durelli L Cochrane Database Syst Rev; 2008 Apr; (2):CD005278. PubMed ID: 18425915 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study. Khan O; Rieckmann P; Boyko A; Selmaj K; Ashtamker N; Davis MD; Kolodny S; Zivadinov R Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905 [TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M; Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398 [TBL] [Abstract][Full Text] [Related]
33. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
34. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Filippi M; Wolinsky JS; Comi G; Lancet Neurol; 2006 Mar; 5(3):213-20. PubMed ID: 16488376 [TBL] [Abstract][Full Text] [Related]
35. Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis. Khan O; Zabad R; Caon C; Zvartau-Hind M; Tselis A; Lisak R CNS Drugs; 2002; 16(8):563-78. PubMed ID: 12096936 [TBL] [Abstract][Full Text] [Related]
36. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Voskuhl RR; Wang H; Wu TC; Sicotte NL; Nakamura K; Kurth F; Itoh N; Bardens J; Bernard JT; Corboy JR; Cross AH; Dhib-Jalbut S; Ford CC; Frohman EM; Giesser B; Jacobs D; Kasper LH; Lynch S; Parry G; Racke MK; Reder AT; Rose J; Wingerchuk DM; MacKenzie-Graham AJ; Arnold DL; Tseng CH; Elashoff R Lancet Neurol; 2016 Jan; 15(1):35-46. PubMed ID: 26621682 [TBL] [Abstract][Full Text] [Related]